BiotechTube

osilodrostat

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cushing's Syndrome

Conditions

Cushing's Syndrome

Trial Timeline

Oct 5, 2018 → Nov 16, 2023

NCT ID
NCT03606408

About osilodrostat

osilodrostat is a phase 2 stage product being developed by Recordati for Cushing's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03606408. Target conditions include Cushing's Syndrome.

What happened to similar drugs?

2 of 10 similar drugs in Cushing's Syndrome were approved

Approved (2) Terminated (1) Active (7)
🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
🔄Pasireotide sub-cutaneousNovartisPhase 3
🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3
🔄PasireotideNovartisPhase 3
✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
🔄mifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT06430528Pre-clinicalRecruiting
NCT05633953Pre-clinicalCompleted
NCT05382156Pre-clinicalActive
NCT03606408Phase 2Completed

Competing Products

18 competing products in Cushing's Syndrome

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
40
Pasireotide sub-cutaneousNovartisPhase 3
40
osilodrostat + osilodrostat PlaceboNovartisPhase 3
40
OsilodrostatNovartisPhase 2
35
PasireotideNovartisPhase 3
40
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
43
SOM230 s.c.NovartisPhase 2
35
Lu AG13909LundbeckPhase 2
39
OsilodrostatRecordatiPre-clinical
23
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
40
OsilodrostatRecordatiPre-clinical
27
mifepristoneCorcept TherapeuticsPhase 3
37
CORT125134Corcept TherapeuticsPhase 2
32
Cushing's syndrome confirmationCorcept TherapeuticsPre-clinical
15
MifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
29